No more Darvon for U.S. market: FDA
Links shared publicly online about this topic.
- 714total visits
No more Darvon for U.S. market: FDA
View full resource at health.yahoo.net
Most Recently Shared on November 20, 2010 at 2:40 am By:
No more Darvon for U.S. market: FDA http://bit.ly/ciDHFS
FDA drug approvals soared in 2011, big year for GSK, J&J - FierceBiotech
fiercebiotech.com — “Safety-conscious U.S. regulators have taken part of the blame for the drug industry's monumental problems, many of which center on an inability to bring enough new products to market. But the FDA can Read more...” View full resource at fiercebiotech.com
Most Recently Shared on January 10, 2012 at 10:21 pm By:
FDA drug approvals soared in 2011, big year for GSK, J&J - FierceBiotech: http://t.co/JrqRjtRE
amednews: AMA delegates detail steps to confront national drug shortage emergency :: Nov. 28, 2011 ... American Medical News
ama-assn.org — “The AMA house backs such recommendations as mandating public notification of market withdrawals up to a year in advance.” View full resource at ama-assn.org
Most Recently Shared on November 28, 2011 at 6:34 am By:
RT @amednews AMA delegates detail steps to confront national drug shortage emergency. http://t.co/W8FkFD1D
Hospira preps PhIII biosimilar study as it grabs lead on new market - FierceBiotech
fiercebiotech.com — “The FDA has caused more than a little grumbling in the payer community with its oh-so-slow approach to hammering out new regulations on the development of biosimilars in the U.S. But there are a Read more...” View full resource at fiercebiotech.com
Most Recently Shared on September 21, 2011 at 2:27 pm By:
Hospira preps PhIII biosimilar study as it grabs lead on new market. http://t.co/jgReEyI0
Hospira preps PhIII biosimilar study as it grabs lead on new market - FierceBiotech
fiercebiotech.com — “The FDA has caused more than a little grumbling in the payer community with its oh-so-slow approach to hammering out new regulations on the development of biosimilars in the U.S. But there are a Read more...” View full resource at fiercebiotech.com
Most Recently Shared on September 21, 2011 at 2:01 pm By:
John Carroll Health Communicator
Hospira preps PhIII biosimilar study as it grabs lead on new market http://t.co/zH2zCDTR
NuPathe: FDA wants more data on migraine patch - MarketWatch
marketwatch.com — “TEL AVIV (MarketWatch) -- NuPathe Inc., the Conshohocken, Pa., specialist in therapeutics for diseases of the central nervous system, said the U.S. Food and Drug Administration declined to approve its proposed migraine patch and wants more information on the drug, called Zelrix. NuPathe said it won't meet its target of launching the patch in first-half 2012. In a Complete Response Letter, NuPathe said in a Tuesday statement, the FDA "acknowledged that NuPathe established the efficacy of” View full resource at marketwatch.com
Most Recently Shared on August 30, 2011 at 12:43 pm By:
NuPathe: FDA wants more data on migraine patch: TEL AVIV (MarketWatch) -- NuPathe Inc., the Conshohocken, Pa., s... http://t.co/8GP0Ewj
FDA clears TearScience to market LipiFlow in U.S. :: Editor's Blog at WRAL Tech Wire
wraltechwire.com — “After more than three years, TearScience's thermal pulsation system for treating evaporative dry eye received federal clearance on Monday to begin commercialization of its LipiFlow system in the United States.” View full resource at wraltechwire.com
Most Recently Shared on July 25, 2011 at 1:57 am By:
Eye Doctor Doctor and Optometrist
FDA approves lipidflow, a device to treat MGD http://t.co/Opp7eEN
Will Ranbaxy plant clear FDA inspection? - FiercePharma
fiercepharma.com — “The FDA has started its inspection of a Ranbaxy Laboratories plant in India--a move that could help the generics maker resume supplies to the U.S. market after nearly three years under an import Read more...” View full resource at fiercepharma.com
Most Recently Shared on June 24, 2011 at 2:56 pm By:
Will Ranbaxy plant clear FDA inspection? http://bit.ly/jUKO2v
Study: Cancer drugs approved in U.S. before Europe | Reuters
reuters.com — “WASHINGTON (Reuters) - New cancer medicines typically reach the U.S. market several months before they go on sale in Europe, according to a study published amid a debate about access to new drugs.The” View full resource at reuters.com
Most Recently Shared on June 16, 2011 at 12:33 pm By:
Raymond DuBois Internist, Gastroenterologist, Health Executive, Physician, and Doctor
New Cancer Drugs Typically Reach US Months Before They Are Available In Europe http://t.co/FJH4wEv via @reuters
Kohl: FDA's Post-Market Review Of Hip Implants Welcome, But More Scrutiny Needed
medicalnewstoday.com — “Today, U.S. Senator Herb Kohl, Chairman of the Special Committee on Aging, wrote Dr. Margaret Hamburg, Commissioner of the Food and Drug Administration (FDA) commending her Agency's recent decisio” View full resource at medicalnewstoday.com
Most Recently Shared on May 25, 2011 at 8:06 am By:
Drugs and Devices OW OW Health
Kohl: FDA's Post-Market Review Of Hip Implants Welcome, But More Scrutiny Needed: Today, U.S. Senator Herb Kohl,... http://bit.ly/k1Ico6
Merck Wins U.S. FDA Panel--™s Backing for Hepatitis C Drug - Bloomberg
bloomberg.com — “Merck & Co. won a U.S. panel--™s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.” View full resource at bloomberg.com
Most Recently Shared on April 28, 2011 at 11:20 am By:
John Carroll Health Communicator
In case you missed it, Merck gets unanimous panel support on boceprevir; list of suggested post-marketing studies. http://bloom.bg/iwYpxP
SEC Charges FDA Chemist With Insider Trading Ahead of Drug Approval Announcements - Timothy Spangler - Law of the Market - Forbes
blogs.forbes.com — “The Securities and Exchange Commission this week charged a U.S. Food and Drug Administration (FDA) chemist with insider trading on confidential information about upcoming announcements of FDA drug approval decisions, generating more than $3.6 million in illicit profits and avoided losses. The SEC alleges that Cheng Yi Liang illegally traded in [...]” View full resource at blogs.forbes.com
Most Recently Shared on April 1, 2011 at 6:53 am By:
Drugs and Devices OW OW Health
SEC Charges FDA Chemist With Insider Trading Ahead of Drug Approval Announcements: The Securities and Exch... http://bit.ly/e2JI4J #drug
FDA Orders Prescription Cold, Allergy Medicines Off the Market - AOL Health
aolhealth.com — “The U.S. Food and Drug Administration ordered more than 500 prescription cough, cold and allergy products off the market Wednesday, saying its office” View full resource at aolhealth.com
Most Recently Shared on March 3, 2011 at 6:00 pm By:
The FDA ordered 500 prescription cough, cold and allergy products off the market. Read which ones arent safe: http://aol.it/gWdZtz
Merck KGaA Fails to Win FDA's Backing for Pill Against Multiple Sclerosis - Bloomberg
bloomberg.com — “Merck KGaA failed to win U.S. regulators--™ backing for its multiple sclerosis pill cladribine, shutting the German drugmaker for now out of the market for new treatments for the crippling disease.” View full resource at bloomberg.com
Most Recently Shared on March 2, 2011 at 8:37 am By:
Merck KGaA Fails to Win FDA's Backing for Pill Against Multiple Sclerosis: U.S. regulators requested more info... http://bloom.bg/hD5BuZ
Delayed FDA Removal of Painkiller Propoxyphene From U.S. Market Has Cost More Than 1,000 U.S. Lives - Jack's posterous
pharmagossip.posterous.com — “Delayed FDA Removal of Painkiller Propoxyphene From U.S. Market Has Cost More Than 1,000 U.S. Lives - Jack's posterous” View full resource at pharmagossip.posterous.com
Most Recently Shared on January 31, 2011 at 7:04 pm By:
Jack Friday - PharmaGossip Health Blog
Delayed FDA Removal of Painkiller Propoxyphene From U.S. Market Has Cost More Than 1,000 U.S. Lives http://post.ly/1YdU8
Tobacco Product Changes Must Be Reviewed by U.S. FDA - Bloomberg
bloomberg.com — “Tobacco companies led by Altria Group Inc. and Reynolds American Inc. must get U.S. Food and Drug Administration approval to sell products introduced or changed in the past four years, a move that may let the agency keep more addictive items off the market.” View full resource at bloomberg.com
Most Recently Shared on January 5, 2011 at 7:27 pm By:
TobaccoFreeKids Health Organization
The FDA is now requiring tobacco industry to prove its newest products are no more harmful than older products. http://bit.ly/gKgfxO
Advertisement
